Edgewise Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Edgewise Therapeutics R&D Spending Growth & History (EWTX)
Edgewise Therapeutics's r&d spending was $151.4M for fiscal 2025.
View full Edgewise Therapeutics company overviewEdgewise Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $151.4M | $24.4M | +19.24% |
| 2024 | 2024-12-31 | $127.0M | $36.1M | +39.67% |
| 2023 | 2023-12-31 | $90.9M | $36.9M | +68.24% |
| 2022 | 2022-12-31 | $54.0M | $21.8M | +67.86% |
| 2021 | 2021-12-31 | $32.2M | $17.2M | +114.84% |
| 2020 | 2020-12-31 | $15.0M | — | — |
Edgewise Therapeutics quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $47.5M | $14.0M | +41.69% |
| Q1 2026 | 2026-03-31 | $42.7M | $5.9M | +16.04% |
| Q4 2025 | 2025-12-31 | $43.6M | $7.2M | +19.86% |
| Q3 2025 | 2025-09-30 | $37.5M | $5.3M | +16.32% |
| Q2 2025 | 2025-06-30 | $33.6M | $2.9M | +9.38% |
| Q1 2025 | 2025-03-31 | $36.8M | $9.1M | +32.73% |
| Q4 2024 | 2024-12-31 | $36.4M | $8.7M | +31.38% |
| Q3 2024 | 2024-09-30 | $32.2M | $8.4M | +35.47% |
| Q2 2024 | 2024-06-30 | $30.7M | $11.1M | +56.86% |
| Q1 2024 | 2024-03-31 | $27.7M | $7.8M | +39.33% |
| Q4 2023 | 2023-12-31 | $27.7M | $11.1M | +66.65% |
| Q3 2023 | 2023-09-30 | $23.8M | $9.9M | +71.20% |
| Q2 2023 | 2023-06-30 | $19.6M | $7.2M | +57.71% |
| Q1 2023 | 2023-03-31 | $19.9M | $8.8M | +78.68% |
| Q4 2022 | 2022-12-31 | $16.6M | $7.5M | +82.79% |
| Q3 2022 | 2022-09-30 | $13.9M | $4.0M | +40.63% |
| Q2 2022 | 2022-06-30 | $12.4M | $4.5M | +57.77% |
| Q1 2022 | 2022-03-31 | $11.1M | $5.8M | +107.54% |
| Q4 2021 | 2021-12-31 | $9.1M | $3.9M | +76.84% |
| Q3 2021 | 2021-09-30 | $9.9M | $6.6M | +205.13% |
| Q2 2021 | 2021-06-30 | $7.9M | $4.2M | +116.02% |
| Q1 2021 | 2021-03-31 | $5.4M | $2.4M | +80.65% |
| Q4 2020 | 2020-12-31 | $5.1M | — | — |
| Q3 2020 | 2020-09-30 | $3.2M | — | — |
| Q2 2020 | 2020-06-30 | $3.6M | — | — |
| Q1 2020 | 2020-03-31 | $3.0M | — | — |
Edgewise Therapeutics r&d spending trends
Over the last five fiscal years, Edgewise Therapeutics's r&d spending increased from $15.0M to $151.4M, a change of $136.4M. The latest reported quarter, Q2 2026, shows $47.5M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Edgewise Therapeutics source filings ↗